🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Adam Reich

University of Rzeszów

ORCID: 0000-0002-5573-1754

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)”.

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

British Journal of Dermatology(2023)10.1093/bjd/ljad252

N/A

0.662DataRank · unranked

22 citations

Jerry Bagel, Stephen K. Tyring, Hwanhee Hong, Lev Pavlovsky, Ronald Vender +11 more

Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances

Advances in Dermatology and Allergology(2020)10.5114/ada.2020.94832

N/A

0DataRank · unranked

65 citations

Bogusław Nedoszytko, Joanna Bartosińska, Aleksandra Batycka-Baran, Rafał Czajkowski, Iwona T. Dobrucki +22 more

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy(2025)10.1111/all.70181

N/A

0DataRank · unranked

0 citations

Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman +18 more